Sign In
Buy RETA
$172.36
+0 (+0%)
At Close: Dec 22, 2023
Reata (RETA) Soars on Potential Omaveloxolone NDA Filing
11:17am, Thursday, 20'th May 2021
The FDA asks Reata (RETA) to submit a pre-NDA meeting request to discuss omaveloxolone study data and cancel its previous request for a more general Type C meeting, boosting chances of an early NDA fi
Why Reata Pharmaceuticals Stock Is Skyrocketing Today
03:34pm, Wednesday, 19'th May 2021
The company might soon be taking a very big step toward FDA approval of an important pipeline drug.
Here's why Reata Pharmaceuticals gained 20% on Wednesday
02:04pm, Wednesday, 19'th May 2021
The U.S. Food and Drug Administration (FDA) sent a communication to Reata Pharmaceuticals Inc. (NASDAQ: RETA) on Wednesday, recommending that it submits a new request for a pre-NDA meeting. The pharma
Reata Pharmaceuticals (RETA) Stock: Over 14% Increase Pre-Market Explanation
09:04am, Wednesday, 19'th May 2021
The stock price of Reata Pharmaceuticals Inc (NASDAQ: RETA) increased by over 14% pre-market. This is why it happened.
Reata Announces that The FDA Has Asked The Company to Request a Pre-NDA Meeting for Omaveloxolone for the Treatment of Friedreich's Ataxia
06:45am, Wednesday, 19'th May 2021
PLANO, Texas, May 19, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced tha
Ceva Among Top Shorts As Indices Pop Amid Low Jobless Claims
11:48am, Thursday, 13'th May 2021
The major indices have all jumped as jobless claims fell to a fresh pandemic low. If you're looking for a way to play this market, the deep learning algorithms at Q.ai have crunched the data to give y
AI Model Rates Redfin And Carvana Top Short Today
11:32am, Wednesday, 12'th May 2021
Going into today, the Dow Jones continued its sell-off and fell more than 150 points while the S&P 500 lost 0.6% and the Nasdaq dipped more than 1%. Our AI has identified the following stocks ra
Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q1 2021 Results - Earnings Call Transcript
11:19pm, Saturday, 08'th May 2021
Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q1 2021 Results - Earnings Call Transcript
Reata Pharmaceuticals, Inc. Announces First Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs
06:45am, Thursday, 06'th May 2021
ANNOUNCES FDA ACCEPTED FOR FILING REATA'S NDA OF BARDOXOLONE FOR THE TREATMENT OF PATIENTS WITH CKD CAUSED BY ALPORT SYNDROME
Reata Pharmaceuticals Announces Presentations at Upcoming Investor Conferences
06:45am, Monday, 03'rd May 2021
PLANO, Texas, May 03, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced tha
Reata Pharmaceuticals, Inc. To Report First Quarter 2021 Financials and To Provide an Update on Development Programs on May 6, 2021
05:00pm, Wednesday, 28'th Apr 2021
PLANO, Texas, April 28, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it will
Strength Seen in Reata Pharmaceuticals, Inc. (RETA): Can Its 3% Jump Turn into More Strength?
10:02am, Wednesday, 28'th Apr 2021
Reata Pharmaceuticals, Inc. (RETA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into furthe
RETA Stock: $155 Target By Barclays
06:50am, Wednesday, 28'th Apr 2021
The shares of Reata Pharmaceuticals Inc (NASDAQ: RETA) have received a price target of $155 by Barclays. These are the details.
Approximately 30,000-60,000 Patients in the United States Are Affected With Alport Syndrome, a Life-Threatening Disease With No Approved Therapies
Reata Announces the Appointments of Christy J. Oliger and Shamim Ruff to Its Board of Directors
06:45am, Thursday, 15'th Apr 2021
PLANO, Texas, April 15, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced t
